Results from the more narrowly defined populations suggest that the greatest clinical benefit associated with neoNIVO + CT relative to conventional therapies may be among patients with stage IIIA and patients whose tumours express PD-L1 (even though numerical benefits were also observed among patients with stage IB-II and PD-L1 < 1%) [32]. This evidence concerns the gene CD274 and neoplasm.